

# Ellen Ritchie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1509449/publications.pdf>

Version: 2024-02-01

26  
papers

902  
citations

840776

11  
h-index

642732

23  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&#x2013;2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402
2	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	1.4	123
3	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4059.	1.6	73
4	The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2014, 38, 1184-1190.	0.8	68
5	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). <i>Journal of Geriatric Oncology</i> , 2020, 11, 107-113.	1.0	38
6	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. <i>European Journal of Cancer</i> , 2021, 146, 107-114.	2.8	36
7	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44.	0.8	25
8	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 297-303.	0.4	19
9	Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. <i>Blood</i> , 2020, 135, 1062-1066.	1.4	19
10	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 349-354.	329.8	18
11	Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 245-247.	0.9	13
12	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. <i>Leukemia and Lymphoma</i> , 2018, 59, 821-828.	1.3	11
13	Results From the Dose Escalation Phase of a Randomized Phase 1&#x2013;2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. <i>Blood</i> , 2012, 120, 414-414.	1.4	11
14	Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60&#x2013;75. <i>Blood</i> , 2010, 116, 655-655.	1.4	10
15	Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. <i>Blood Advances</i> , 2022, 6, 3812-3820.	5.2	9
16	Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.3	6
17	Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 1881-1881.	1.4	6
18	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. <i>Blood</i> , 2020, 136, 31-32.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias. <i>Blood</i> , 2008, 112, 2984-2984.	1.4	4
20	Hematopoietic fitness of <i>JAK2V617F</i> myeloproliferative neoplasms is linked to clinical outcome. <i>Blood Advances</i> , 2022, 6, 5477-5481.	5.2	4
21	A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia.. <i>Blood</i> , 2010, 116, 1334-1334.	1.4	1
22	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. <i>Blood</i> , 2013, 122, 1548-1548.	1.4	1
23	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2021, 138, 627-627.	1.4	1
24	A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia. <i>Blood</i> , 2011, 118, 3030-3030.	1.4	0
25	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs FLAG-M) in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years Old (PALG-AML1/2016). <i>Blood</i> , 2020, 136, 3-4.	1.4	0
26	Pain and Opioid Use in Patients with <i>FLT3</i> Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial. <i>Blood</i> , 2020, 136, 25-26.	1.4	0